JP2020076692A - Manufacturing method of latex particle for measuring anti-streptolysin o - Google Patents

Manufacturing method of latex particle for measuring anti-streptolysin o Download PDF

Info

Publication number
JP2020076692A
JP2020076692A JP2018211251A JP2018211251A JP2020076692A JP 2020076692 A JP2020076692 A JP 2020076692A JP 2018211251 A JP2018211251 A JP 2018211251A JP 2018211251 A JP2018211251 A JP 2018211251A JP 2020076692 A JP2020076692 A JP 2020076692A
Authority
JP
Japan
Prior art keywords
reagent
streptolysin
latex particles
latex
slo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018211251A
Other languages
Japanese (ja)
Other versions
JP7225713B2 (en
Inventor
洋輔 角田
Yosuke Tsunoda
洋輔 角田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyobo Co Ltd
Original Assignee
Toyobo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyobo Co Ltd filed Critical Toyobo Co Ltd
Priority to JP2018211251A priority Critical patent/JP7225713B2/en
Publication of JP2020076692A publication Critical patent/JP2020076692A/en
Application granted granted Critical
Publication of JP7225713B2 publication Critical patent/JP7225713B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

To provide an anti-streptolysin O measurement reagent allowing a high sensitivity by using a small amount of streptolysin O.SOLUTION: A manufacturing method of a latex particle for measuring an anti-streptolysin O includes: using a latex particle having a carboxyl group on its surface; covalent-binding a streptolysin O to the latex particle; performing a blocking processing; and then performing cleaning process with a buffer solution including a surfactant, for example Tween20.SELECTED DRAWING: None

Description

本発明は抗ストレプトリジンO測定試薬(以下、「ASO試薬」と表記することもある。)に用いられるラテックス粒子の製造方法に関する。より詳しくは、ストレプトリジンOを使用したラテックス凝集比濁法を測定原理とした抗ストレプトリジンO測定ラテックス粒子の製造方法に関する。   The present invention relates to a method for producing latex particles used as an anti-streptolidine O measuring reagent (hereinafter sometimes referred to as “ASO reagent”). More specifically, the present invention relates to a method for producing latex particles for measuring anti-streptolysin O using a latex aggregation turbidimetric method using streptolidine O as a measurement principle.

ラテックス凝集比濁法を測定原理とした測定試薬を製造するためには、測定対象物質と結合する抗体もしくは抗原をラテックス粒子に感作する必要がある。例えば、溶血性連鎖球菌(Streptococcus pyogenes)が菌体外に生産するストレプトリジンO(以下、「SLO」と表記することもある。)をラテックス粒子に感作すれば、SLOに対する抗体価(ASO価)を測定することが可能であり、SLOは溶血性連鎖球菌の感染有無を診断するためのASO測定試薬の原料として広く使用されている。   In order to produce a measurement reagent based on the latex aggregation turbidimetric method, it is necessary to sensitize latex particles with an antibody or an antigen that binds to a substance to be measured. For example, when the latex particles are sensitized with streptolysin O (hereinafter also referred to as “SLO”) produced outside the cells by Streptococcus pyogenes, the antibody titer against SLO (ASO titer) can be obtained. ) Can be measured, and SLO is widely used as a raw material of an ASO measuring reagent for diagnosing the presence or absence of infection with hemolytic streptococcus.

従来はラテックス粒子とSLOとの疎水性相互作用による物理的吸着法が広く採られ、得られたラテックス粒子とSLOとの複合体をBSAなどの免疫学的に不活性なタンパク質を溶解した緩衝液に懸濁した試薬の状態で保存するのが一般的であった(特許文献1)。しかし、このようにして調製された試薬では試薬を調製する条件により、担体同士の自己凝集が起こったり、感作したSLOの脱離などが起こったりして試薬の反応性が低下し、本来の測定性能が発揮できない場合があった。そこで、ラテックス粒子とSLOとを共有結合させることにより、SLOの脱離を防止して試薬の安定性を向上させる方法が提案されている(特許文献2、3)。
しかしながら、特許文献2や特許文献3で使用されているホウ酸緩衝溶液に含まれるホウ酸化合物は、ヨーロッパのREACH規制の認可対象物質リストに収載されている高懸念物質であるため、ホウ酸化合物を使用しない製法を開発することが望まれていた。
Conventionally, a physical adsorption method based on hydrophobic interaction between latex particles and SLO has been widely adopted, and the obtained complex of latex particles and SLO is a buffer solution in which an immunologically inactive protein such as BSA is dissolved. It was generally stored in the form of a reagent suspended in (Patent Document 1). However, in the reagent thus prepared, the reactivity of the reagent decreases due to self-aggregation of the carriers with each other or desorption of the sensitized SLO depending on the conditions for preparing the reagent. In some cases, the measurement performance could not be exhibited. Therefore, a method has been proposed in which the latex particles and SLO are covalently bonded to prevent the SLO from being desorbed and improve the stability of the reagent (Patent Documents 2 and 3).
However, since the boric acid compound contained in the borate buffer solution used in Patent Document 2 or Patent Document 3 is a substance of high concern listed in the list of substances subject to authorization under the European REACH regulation, the boric acid compound It was desired to develop a manufacturing method that does not use

一方で、物理吸着法とは異なり、共有結合によるラテックス試薬の調製においては、共有結合の種類、ラテックス粒子の種類、抗体もしくは抗原を感作させる条件、ブロッキング条件、洗浄条件、ラテックス粒子の最終保存緩衝液の種類など試薬性能に与えるファクターが多数存在し、それらの条件を体系的に評価し、最適な条件を見出すことは非常に困難であった。 On the other hand, unlike the physical adsorption method, in the preparation of a latex reagent by covalent bonding, the type of covalent bond, the type of latex particles, the conditions for sensitizing antibodies or antigens, the blocking conditions, the washing conditions, the final storage of latex particles There are many factors that affect the reagent performance such as the type of buffer solution, and it was very difficult to systematically evaluate those conditions and find the optimum conditions.

特開平5−203642号公報JP-A-5-203642 特開2003−344410号公報JP, 2003-344410, A 特許第4704662号公報Japanese Patent No. 4704662

本発明は、かかる現状に鑑み創作されたものであり、その目的は少量のSLOで、高い感度が得られるASO試薬を提供することにある。   The present invention has been made in view of such a situation, and an object thereof is to provide an ASO reagent that can obtain high sensitivity with a small amount of SLO.

本発明者は測定試薬の安定性を高めるために鋭意探索した結果、ブロッキング後の洗浄バッファーに界面活性剤、特に好ましくはTween20(ポリオキシエチレンソルビタンモノラウラート)を添加すれば試薬の安定性が向上することを見出し、本発明を完成させるに至った。   The present inventors have conducted extensive studies to improve the stability of the measurement reagent, and as a result, the stability of the reagent can be improved by adding a surfactant, particularly preferably Tween 20 (polyoxyethylene sorbitan monolaurate), to the washing buffer after blocking. The inventors have found that it is improved and have completed the present invention.

すなわち、本発明は、以下の列挙するものが例示される。
[項1]
カルボキシル基を表面に有するラテックス粒子を使用し、ストレプトリジンOをラテックス粒子に共有結合させ、ブロッキング処理を行った後、界面活性剤を含む緩衝液での洗浄工程を含む抗ストレプトリジンO測定用ラテックス粒子の製造方法。
[項2]
Tween20、TritonX−100、CHAPS、SDS及びデオキシコール酸からなる群より選択される少なくとも1種の界面活性剤を用いる項1に記載の抗ストレプトリジンO測定用ラテックス粒子の製造方法。
[項3]
界面活性剤がTween20を用いる項2に記載の抗ストレプトリジンO測定用ラテックス粒子の製造方法。
[項4]
界面活性剤の緩衝液中における濃度が0.01%から0.1%である項1から3のいずれかに記載の抗ストレプトリジンO測定試薬。
That is, the present invention is exemplified by those listed below.
[Item 1]
Latex for measuring anti-streptolysin O including a step of washing with a buffer solution containing a surfactant after using latex particles having a carboxyl group on the surface thereof, covalently binding streptolysin O to the latex particles, and performing a blocking treatment. Method for producing particles.
[Item 2]
Item 2. The method for producing latex particles for measuring anti-streptolysin O according to Item 1, which uses at least one surfactant selected from the group consisting of Tween 20, Triton X-100, CHAPS, SDS, and deoxycholic acid.
[Item 3]
Item 3. The method for producing latex particles for measuring anti-streptolysin O according to Item 2, wherein the surfactant is Tween20.
[Item 4]
Item 4. The anti-streptolidine O measurement reagent according to any one of Items 1 to 3, wherein the concentration of the surfactant in the buffer is 0.01% to 0.1%.

本発明のASO試薬に用いるラテックス粒子の製造方法は、少量のSLOを用いた場合であっても、感度の高い測定を可能とする点で有用である。   The method for producing latex particles used for the ASO reagent of the present invention is useful in that it enables highly sensitive measurement even when a small amount of SLO is used.

(SLO)
本発明に用いるSLOとしては、特に限定されず、例えば、溶血性連鎖球菌(Streptococcus pyogenes)が菌体外に生産するSLOや組換え大腸菌などを用いて生産された遺伝子組換えのSLO、また、一部のアミノ酸配列を欠損させた改変型のSLO、さらにはMBPなどを融合させた融合型SLOを使用しても良い。例えば、WO2017/204325に開示されているSLOが具体的に例示される。
(SLO)
The SLO used in the present invention is not particularly limited, and examples thereof include gene-recombinant SLO produced by using SLO or recombinant E. coli produced by Streptococcus pyogenes extracellularly, A modified SLO in which a part of the amino acid sequence is deleted, or a fused SLO in which MBP or the like is fused may be used. For example, the SLO disclosed in WO2017 / 204325 is specifically exemplified.

(ラテックス粒子)
本発明に用いるラテックス粒子としては、特に限定されないが、例えば、スチレンスルホン酸、メタクリル酸、アクリル酸、アクリル酸エステルなどを共重合させたポリスチレン粒子にカルボキシル基を導入した共有結合法向けのラテックス粒子が挙げられる。また、物理吸着を抑制するため、つまり、親水度を高めるためにポリアクリルアミドを含んだラテックス粒子を使用することもできる。好ましくは、アクリル酸を共重合させたポリスチレン粒子が挙げられ、さらに好ましくはポリアクリルアミドにより親水度が高められたアクリル酸を共重合させたポリスチレン粒子が挙げられる。
(Latex particles)
The latex particles used in the present invention are not particularly limited, but for example, latex particles for a covalent bonding method in which a carboxyl group is introduced into polystyrene particles obtained by copolymerizing styrenesulfonic acid, methacrylic acid, acrylic acid, acrylic acid ester and the like. Is mentioned. Also, latex particles containing polyacrylamide can be used in order to suppress physical adsorption, that is, in order to increase hydrophilicity. Preferred are polystyrene particles copolymerized with acrylic acid, and more preferred are polystyrene particles copolymerized with acrylic acid whose hydrophilicity is increased by polyacrylamide.

カルボキシル基の導入効率は適宜選択されるが、好ましくは50μeq/g〜300μeq/g、より好ましくは70μeq/g〜250μeq/g、さらに好ましくは90μeq/g〜200μeq/gの割合でカルボキシル基が導入されたラテックス粒子である。 The introduction efficiency of the carboxyl group is appropriately selected, but preferably 50 μeq / g to 300 μeq / g, more preferably 70 μeq / g to 250 μeq / g, and further preferably 90 μeq / g to 200 μeq / g. Latex particles.

使用するラテックス粒子の平均粒径は、目的・用途に応じて適宜選択されるが、本発明においては、自動分析機向けであれば、好ましくは50nm〜250nm、より好ましくは60nm〜200nm、さらに好ましくは70nm〜150nmの粒径のラテックス粒子であることが好ましい。また、目視判断用の試薬向けであれば、好ましくは100nm〜500nm、よりこのましくは200nm〜400nmのラテックス粒子であることが好ましい。 The average particle size of the latex particles used is appropriately selected according to the purpose and application, but in the present invention, if it is for an automatic analyzer, it is preferably 50 nm to 250 nm, more preferably 60 nm to 200 nm, further preferably Is preferably latex particles having a particle size of 70 nm to 150 nm. Further, for a reagent for visual judgment, latex particles having a particle size of preferably 100 nm to 500 nm, more preferably 200 nm to 400 nm are preferable.

(SLOをラテックス粒子へ感作する方法)
ラテックス粒子の表面に有するカルボキシル基にSLOのアミノ基を結合させる方法としては、特に限定されるものではないが、例えば、1−エチル−3−(3−ジメチルアミノプロピル)カルボジイミド塩酸塩(EDC)などの水溶性カルボジイミドが使用できる。N−ヒドロキシスクシンイミドを併用して、不安定なアシルイソ尿素中間体を、アミンと反応しやすいより安定したスクシンイミジルエステルに変換させてもよい。
(Method of sensitizing SLO to latex particles)
The method for binding the amino group of SLO to the carboxyl group on the surface of the latex particles is not particularly limited, but for example, 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) Water soluble carbodiimides such as N-hydroxysuccinimide may be used in combination to convert the labile acylisourea intermediate to a more stable succinimidyl ester that is more reactive with amines.

(ブロッキング)
また、本発明の免疫測定試薬においては、非特異反応を抑制するためや免疫測定試薬自体の安定性を高めるために、特に限定されるものではないが、例えば、アルブミン、カゼイン、ゼラチンなどの蛋白質、これら蛋白質の分解物、アミノ酸、界面活性剤等の1種類もしくは2種類以上を前記不溶性担体に更に担持させても良い。ブロッキング剤の濃度は適宜決められるが、好ましくは0.1%〜5%、さらに好ましくは1%〜3%である。処理温度についても適宜決められるが、好ましくは4℃〜30℃、さらに好ましくは4℃〜20℃である。処理時間についても適宜決められるが、好ましくは0.5時間〜24時間、さらに好ましくは1時間〜16時間である。
(blocking)
In addition, the immunoassay reagent of the present invention is not particularly limited in order to suppress non-specific reactions and to enhance the stability of the immunoassay reagent itself, but examples thereof include proteins such as albumin, casein, and gelatin. One or more of these protein degradation products, amino acids, and surfactants may be further supported on the insoluble carrier. Although the concentration of the blocking agent is appropriately determined, it is preferably 0.1% to 5%, more preferably 1% to 3%. The treatment temperature is also appropriately determined, but is preferably 4 ° C to 30 ° C, more preferably 4 ° C to 20 ° C. The treatment time is also appropriately determined, but it is preferably 0.5 hour to 24 hours, more preferably 1 hour to 16 hours.

(洗浄)
ブロッキング反応後の洗浄工程においては、各種界面活性剤を含む緩衝液での洗浄を実施することが望ましい。界面活性剤としては、Tween20、TritonX−100(ポリエチレングリコールモノ−p−イソオクチルフェニルエーテル)、CHAPS(3−[(3−コラミドプロピル)ジメチルアンモニオ]−1−プロパンスルホナート)、SDS(ドデシル硫酸ナトリウム)、デオキシコール酸などが挙げられる。これらの界面活性剤は単独で用いてもよいし、複数種を組み合わせて用いてもよい。使用濃度は適宜決められるが、例えば、0.1%のTween20を含むリン酸緩衝生理食塩水(pH7.4)などが好適である。
(Washing)
In the washing step after the blocking reaction, it is desirable to carry out washing with a buffer solution containing various surfactants. As the surfactant, Tween 20, Triton X-100 (polyethylene glycol mono-p-isooctyl phenyl ether), CHAPS (3-[(3-colamidopropyl) dimethylammonio] -1-propanesulfonate), SDS ( Sodium dodecyl sulfate), deoxycholic acid and the like. These surfactants may be used alone or in combination of two or more. The concentration to be used can be appropriately determined, but for example, phosphate buffered saline (pH 7.4) containing 0.1% Tween 20 is suitable.

(測定試薬)
本発明において、ASO試薬は、2つの試薬から構成されてなり、緩衝溶液を第1試薬、ストレプトリジンOを感作したラテックス粒子を含むラテックス試液を第2試薬とする構成からなるものである。そして、第1試薬の緩衝溶液中にポリビニルピロリドンを含有することを、好ましい構成とする。
(Measurement reagent)
In the present invention, the ASO reagent is composed of two reagents, and the buffer solution is the first reagent and the latex reagent solution containing latex particles sensitized with streptolidine O is the second reagent. Then, it is preferable that the buffer solution of the first reagent contains polyvinylpyrrolidone.

本発明の免疫測定法としては、本発明のASO試薬を用いるのであれば特に限定されず、通常の方法により行うことができる。例えば、被測定物質を含む媒体に本発明の免疫測定試薬を加え、被測定物質と本発明の免疫測定試薬に含まれるラテックス粒子上に固定された抗原とが抗原抗体反応により結合して生じた凝集を、光学的に観察または目視により観察する。抗原抗体反応のpHの好ましい下限は5、上限は10であり、より好ましい下限は6、上限は9である。反応の温度の好ましい下限は4℃、上限は50℃であり、より好ましい下限は20℃、上限は40℃である。反応時間は適宜決められるが、第2試薬と混合後、1〜10分間程度反応させることが望ましい。目視により観察して判定する方法としては、例えば、試料と本発明の免疫測定試薬とを、判定板上にて室温で混合し、1〜5分間揺り動かしたあと、凝集の有無を判定する方法等が挙げられる   The immunoassay method of the present invention is not particularly limited as long as it uses the ASO reagent of the present invention, and can be performed by a usual method. For example, the immunoassay reagent of the present invention was added to a medium containing the substance to be measured, and the substance to be measured and the antigen immobilized on the latex particles contained in the immunoassay reagent of the present invention were bound to each other by an antigen-antibody reaction to generate. Aggregation is observed optically or visually. The preferable lower limit of the pH of the antigen-antibody reaction is 5, the upper limit is 10, and the more preferable lower limit is 6 and the upper limit is 9. The preferable lower limit of the reaction temperature is 4 ° C and the upper limit thereof is 50 ° C, and the more preferable lower limit thereof is 20 ° C and the upper limit thereof is 40 ° C. Although the reaction time is appropriately determined, it is desirable that the reaction is performed for about 1 to 10 minutes after mixing with the second reagent. As a method for visually observing and determining, for example, a method in which a sample and the immunoassay reagent of the present invention are mixed on a determination plate at room temperature and shaken for 1 to 5 minutes, and then the presence or absence of aggregation is determined, etc. Can be mentioned

上記媒体としては、被測定物質の種類に応じて適当な各種緩衝液が用いられる。係る緩衝液としては、被測定物質を失活させることがなく、かつ、抗原抗体反応を阻害しないようなイオン濃度やpHを有するものであればよく、例えば、リン酸緩衝液、グリシン緩衝液、トリス緩衝液、各種グッド緩衝液等の緩衝液が好適に挙げられる。これらの緩衝液は単独で用いてもよく、2種以上を併用してもよい。   As the medium, various buffer solutions suitable for the type of the substance to be measured are used. The buffer solution may be one that does not inactivate the substance to be measured, and has an ion concentration or pH that does not inhibit the antigen-antibody reaction, for example, a phosphate buffer solution, a glycine buffer solution, Buffer solutions such as Tris buffer and various Good's buffers are preferred. These buffer solutions may be used alone or in combination of two or more kinds.

上記媒体は、反応の感度を高めるために、水溶性添加剤、例えばポリエチレングリコール、カルボキシルメチルセルロース、メチルセルロース、デキストラン、ポリビニルピロリドン、ポリグリコシルエチルメタクリレート、プルラン、デキストラン、エルシナン等の水溶性高分子等を含有してもよい。また、特異性の向上、試薬の安定性向上等の目的から、カゼイン、ゼラチン等のタンパク質又はその分解物、変性物;塩化コリン等の第4級アンモニウム塩、EDTA、ポリアニオン、カオトロピックイオン(Cl−,I−,SCN−等)、アミノ酸、界面活性剤等を含有してもよい。   The medium contains a water-soluble additive such as polyethylene glycol, carboxymethyl cellulose, methyl cellulose, dextran, polyvinylpyrrolidone, polyglycosylethyl methacrylate, pullulan, dextran, or erucinan in order to enhance the sensitivity of the reaction. You may. For the purpose of improving specificity and reagent stability, proteins such as casein and gelatin, or degradation products thereof, denatured products; quaternary ammonium salts such as choline chloride, EDTA, polyanions, chaotropic ions (Cl- , I-, SCN-, etc.), amino acids, surfactants and the like.

特に好ましい態様の一例を挙げると、特に第1試薬においてポリビニルピロリドンを使用することが望ましい。第1試薬に添加するポリビニルピロリドンの濃度としては、第1試薬溶液の最終濃度として、0.05%〜0.4%、より好ましくは0.07%〜0.36%、さらに好ましくは0.09%〜0.33%、特に好ましくは0.1%〜0.3%が望ましい。 As an example of a particularly preferred embodiment, it is particularly desirable to use polyvinylpyrrolidone in the first reagent. The concentration of polyvinylpyrrolidone added to the first reagent is 0.05% to 0.4%, more preferably 0.07% to 0.36%, still more preferably 0. 09% to 0.33%, particularly preferably 0.1% to 0.3% is desirable.

(ASO試薬の評価方法)
ASO試薬の性能としては、検出感度、測定範囲、測定精度、再現性、安定性などの項目が挙げられる。本発明によれば、ラテックス粒子をブロッキングした際の洗浄バッファーにTween20を添加すれば、長期間、試薬が安定となる。当該安定性は加速試験により、評価することができる。一般的にラテックス試薬は、通常2〜10℃で保存される。このような試薬の長期間の保存安定性を評価するために、20〜40℃で短期間保存後の性能評価を行う加速試験が実施される。使用される温度としては37℃で行う加速試験が好ましい。尚、測定に用いたASO試薬の単位(IU/ml)は、世界保健機関(WHO)が定めた抗ストレプトリジンO抗体の国際単位に基づいたものである。
(ASO reagent evaluation method)
The performance of the ASO reagent includes items such as detection sensitivity, measurement range, measurement accuracy, reproducibility, and stability. According to the present invention, the reagent becomes stable for a long period of time when Tween 20 is added to the washing buffer when the latex particles are blocked. The stability can be evaluated by an acceleration test. Generally, the latex reagent is usually stored at 2 to 10 ° C. In order to evaluate the long-term storage stability of such a reagent, an accelerated test is carried out at 20 to 40 ° C. for performance evaluation after short-term storage. The temperature used is preferably an accelerated test conducted at 37 ° C. The unit (IU / ml) of the ASO reagent used for the measurement is based on the international unit of anti-streptolidine O antibody determined by the World Health Organization (WHO).

以下に、本発明を実施例により具体的に説明する。なお、本発明は、実施例に限定されるものではない。   The present invention will be specifically described below with reference to examples. The present invention is not limited to the embodiments.

[実施例1]ASOラテックス試薬(第2試薬)の調製
メルク社製カルボキシル基導入ラテックス粒子(製品番号:PSI90−21)0.14mLを遠心分離し、上清を抜き取った。次に50mM MES(pH4.5)を1mL添加し、十分に懸濁した。その後、再び遠心分離を行い、上清を抜き取った。さらに、50mM MES(pH4.5)を0.7mL添加した。これに4%カルボジイミド(EDC)0.35mL及び2.4%N−ヒドロキシスクシンイミド(NHS)0.35mLを加えて、ラテックス粒子の1%濃度とした状態で、25℃で15分撹拌し、カルボキシル基を活性化した後、遠心分離を行い、上清を抜き取った。これに50mM カリウムリン酸緩衝液(以下、「KPB」と示す。)(pH6.5)を0.7mL添加し、再び、遠心分離を行い、上清を抜き取った。これに50mM KPB(pH6.5)を0.7mL添加し、超音波にて分散させることで、活性化ラテックス粒子とした。WO/2017/204325の実施例2に記載の方法で調製したストレプトリジンO(SLO)を3.0(mg/mL)の濃度になるよう50mM KPB(pH6.5)で溶解した。次に、活性化ラテックス粒子0.7mLとSLO溶液0.7mLを混合し、25℃にて2時間撹拌混合することで、SLOをラテックス粒子に共有結合させた。
[Example 1] Preparation of ASO latex reagent (second reagent) 0.14 mL of carboxyl group-introduced latex particles (product number: PSI90-21) manufactured by Merck & Co., Inc. was centrifuged, and the supernatant was extracted. Next, 1 mL of 50 mM MES (pH 4.5) was added and sufficiently suspended. Then, centrifugation was performed again and the supernatant was extracted. Furthermore, 0.7 mL of 50 mM MES (pH 4.5) was added. To this, 0.35 mL of 4% carbodiimide (EDC) and 0.35 mL of 2.4% N-hydroxysuccinimide (NHS) were added, and the mixture was stirred at 25 ° C. for 15 minutes under a state where the latex particles had a concentration of 1%. After activating the group, centrifugation was performed and the supernatant was removed. To this, 0.7 mL of 50 mM potassium phosphate buffer (hereinafter referred to as "KPB") (pH 6.5) was added, the mixture was centrifuged again, and the supernatant was removed. 0.7 mL of 50 mM KPB (pH 6.5) was added thereto and dispersed by ultrasonic waves to obtain activated latex particles. Streptolysin O (SLO) prepared by the method described in Example 2 of WO / 2017/204325 was dissolved in 50 mM KPB (pH 6.5) to a concentration of 3.0 (mg / mL). Next, 0.7 mL of the activated latex particles and 0.7 mL of the SLO solution were mixed and stirred and mixed at 25 ° C. for 2 hours to covalently bond the SLO to the latex particles.

次に、遠心分離を行い、上清を除去した後、ブロッキンング溶液(2%BSAを含む1×PBS(pH7.4))で2mLに再懸濁した。再び、遠心分離により、上清を除去し、1.4mLのブロッキング溶液を添加し、超音波にて分散させた後、4℃で一晩、撹拌した。その後、遠心分離を行い、上清を除去し、最終緩衝液(0.5%BSA及び0.05%アジ化ナトリウムを含む1×PBS(pH7.4))1.4mLに再懸濁した。ここで、上記最終緩衝液中でのTween20の影響を確認するため、Tween20を終濃度0.01%となるよう添加した水準、Tween20を終濃度0.1%となるよう添加した水準、合計3つの水準で試薬を調製した。続いて、超音波にて分散させた後、4℃で1時間、撹拌した。再び、遠心分離により、上清を除去し、2mLの最終緩衝液を添加し、超音波にて十分に分散させた後、2.67mLの最終緩衝液を添加して、第2試薬とした。 Next, centrifugation was performed to remove the supernatant, and then the cells were resuspended in 2 mL with a blocking solution (1 × PBS (pH 7.4) containing 2% BSA). The supernatant was removed again by centrifugation, 1.4 mL of the blocking solution was added, and the mixture was ultrasonically dispersed, and then stirred overnight at 4 ° C. Then, centrifugation was performed, the supernatant was removed, and the cells were resuspended in 1.4 mL of a final buffer solution (1 × PBS (pH 7.4) containing 0.5% BSA and 0.05% sodium azide). Here, in order to confirm the effect of Tween 20 in the final buffer solution, the level at which Tween 20 was added to a final concentration of 0.01% and the level at which Tween 20 was added to a final concentration of 0.1%, a total of 3 The reagents were prepared at two levels. Then, after dispersing with ultrasonic waves, the mixture was stirred at 4 ° C. for 1 hour. Again, the supernatant was removed by centrifugation, 2 mL of the final buffer solution was added, and the mixture was sufficiently dispersed by ultrasonic waves, and then 2.67 mL of the final buffer solution was added to obtain the second reagent.

[実施例2]ASOラテックス試薬(第2試薬)の安定性評価
本発明のASOラテックス試薬における第1試薬としては、0.5%BSAを含む1×PBS(pH7.4)を調製した。次に、自動分析装置日立7180(日立ハイテクノロジーズ製)を用いて、実施例1で調製した各第2試薬の試薬調製直後の感度を測定した。まず、第1試薬120μlに各濃度(0、125、250IU/ml)のASO標準液1.5μlを添加撹拌し、37℃で適時保持した後、第2試薬30μlを添加撹拌し、この後、300秒後から600秒後間の波長546nmでの吸光度変化(ΔmAbs)を評価した。続いて、実施例1で作製した第2試薬をボトルに入れ密栓し、37℃のインキュベーターに入れて加速試験を行った。保存後7日後にインキュベーターより取り出し、再び、感度を測定し、測定値の変化を評価した。その結果、表1に示した通り、洗浄バッファーに含むTween20の濃度依存的に試薬の安定性が向上することを見出した。
[Example 2] Stability evaluation of ASO latex reagent (second reagent) As the first reagent in the ASO latex reagent of the present invention, 1 x PBS (pH 7.4) containing 0.5% BSA was prepared. Next, using an automatic analyzer Hitachi 7180 (manufactured by Hitachi High Technologies), the sensitivity of each second reagent prepared in Example 1 immediately after the reagent preparation was measured. First, to 120 μl of the first reagent, 1.5 μl of ASO standard solution of each concentration (0, 125, 250 IU / ml) was added and stirred, and the mixture was kept at 37 ° C. for an appropriate time, and then 30 μl of the second reagent was added and stirred, and then The change in absorbance (ΔmAbs) at a wavelength of 546 nm from 300 seconds to 600 seconds was evaluated. Subsequently, the second reagent prepared in Example 1 was placed in a bottle, sealed, and placed in a 37 ° C. incubator for an accelerated test. Seven days after storage, the sample was taken out from the incubator, the sensitivity was measured again, and the change in the measured value was evaluated. As a result, as shown in Table 1, it was found that the stability of the reagent was improved depending on the concentration of Tween 20 contained in the washing buffer.

本発明は、測定感度に優れた診断薬として、特に医療分野において有用な技術を提供するである。   The present invention provides a technique useful as a diagnostic agent having excellent measurement sensitivity, particularly in the medical field.

Claims (4)

カルボキシル基を表面に有するラテックス粒子を使用し、ストレプトリジンOをラテックス粒子に共有結合させ、ブロッキング処理を行った後、界面活性剤を含む緩衝液での洗浄工程を含む抗ストレプトリジンO測定用ラテックス粒子の製造方法。 Latex for measuring anti-streptolysin O including a step of washing with a buffer solution containing a surfactant after using latex particles having a carboxyl group on the surface, covalently binding streptolysin O to the latex particles, and performing a blocking treatment. Method for producing particles. Tween20、TritonX−100、CHAPS、SDS及びデオキシコール酸からなる群より選択される少なくとも1種の界面活性剤を用いる請求項1に記載の抗ストレプトリジンO測定用ラテックス粒子の製造方法。 The method for producing latex particles for measuring anti-streptolidine O according to claim 1, wherein at least one kind of surfactant selected from the group consisting of Tween 20, Triton X-100, CHAPS, SDS and deoxycholic acid is used. 界面活性剤がTween20を用いる請求項2に記載の抗ストレプトリジンO測定用ラテックス粒子の製造方法。 The method for producing latex particles for measuring anti-streptolysin O according to claim 2, wherein the surfactant is Tween 20. 界面活性剤の緩衝液中における濃度が0.01%から0.1%である請求項1から3のいずれかに記載の抗ストレプトリジンO測定試薬。 The anti-streptolidine O measuring reagent according to claim 1, wherein the concentration of the surfactant in the buffer is 0.01% to 0.1%.
JP2018211251A 2018-11-09 2018-11-09 Method for producing latex particles for anti-streptolysin O measurement Active JP7225713B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018211251A JP7225713B2 (en) 2018-11-09 2018-11-09 Method for producing latex particles for anti-streptolysin O measurement

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018211251A JP7225713B2 (en) 2018-11-09 2018-11-09 Method for producing latex particles for anti-streptolysin O measurement

Publications (2)

Publication Number Publication Date
JP2020076692A true JP2020076692A (en) 2020-05-21
JP7225713B2 JP7225713B2 (en) 2023-02-21

Family

ID=70724495

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018211251A Active JP7225713B2 (en) 2018-11-09 2018-11-09 Method for producing latex particles for anti-streptolysin O measurement

Country Status (1)

Country Link
JP (1) JP7225713B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112500514A (en) * 2020-11-11 2021-03-16 四川迈克生物新材料技术有限公司 Polystyrene latex microsphere and preparation method thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62195556A (en) * 1985-12-23 1987-08-28 ジヤンセン・フア−マシユ−チカ・ナ−ムロ−ゼ・フエンノ−トシヤツプ Novel detection method of specific bonding agents and bondable substances corresponding to these bonding agent
JPH03269362A (en) * 1990-03-20 1991-11-29 Toyo Ink Mfg Co Ltd Immunity analying reagent and its analyzing method
JPH08146004A (en) * 1994-11-15 1996-06-07 Asahi Chem Ind Co Ltd Determination of anti-streptolysin o antibody
JP2001503861A (en) * 1996-10-30 2001-03-21 テンプル ユニバーシティ―オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション Solid-phase immunoassay
JP2003344410A (en) * 2002-05-23 2003-12-03 Sekisui Chem Co Ltd Immuno-measurement reagent and immuno-measurement method
JP2016075645A (en) * 2014-10-09 2016-05-12 デンカ生研株式会社 Method for analyzing immunity and reagent
WO2017204325A1 (en) * 2016-05-27 2017-11-30 東洋紡株式会社 Modified streptolysin o

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62195556A (en) * 1985-12-23 1987-08-28 ジヤンセン・フア−マシユ−チカ・ナ−ムロ−ゼ・フエンノ−トシヤツプ Novel detection method of specific bonding agents and bondable substances corresponding to these bonding agent
JPH03269362A (en) * 1990-03-20 1991-11-29 Toyo Ink Mfg Co Ltd Immunity analying reagent and its analyzing method
JPH08146004A (en) * 1994-11-15 1996-06-07 Asahi Chem Ind Co Ltd Determination of anti-streptolysin o antibody
JP2001503861A (en) * 1996-10-30 2001-03-21 テンプル ユニバーシティ―オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション Solid-phase immunoassay
JP2003344410A (en) * 2002-05-23 2003-12-03 Sekisui Chem Co Ltd Immuno-measurement reagent and immuno-measurement method
JP2016075645A (en) * 2014-10-09 2016-05-12 デンカ生研株式会社 Method for analyzing immunity and reagent
WO2017204325A1 (en) * 2016-05-27 2017-11-30 東洋紡株式会社 Modified streptolysin o

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112500514A (en) * 2020-11-11 2021-03-16 四川迈克生物新材料技术有限公司 Polystyrene latex microsphere and preparation method thereof

Also Published As

Publication number Publication date
JP7225713B2 (en) 2023-02-21

Similar Documents

Publication Publication Date Title
US3857931A (en) Latex polymer reagents for diagnostic tests
JP4668768B2 (en) Immunoassay method and non-specific reaction suppression method
JP5239340B2 (en) Antigen measurement method and kit used therefor
CN107942069A (en) A kind of NGAL latex immunoturbidimetries detection kit and preparation method thereof
EP2287609B1 (en) Method for production of insoluble carrier particle, insoluble carrier particle, measurement reagent, sample analysis tool, and immunology turbidimetric method
CN108593641B (en) Kit and method for quantitatively detecting substance to be detected in whole blood sample
JP4704662B2 (en) Immunological latex turbidimetric analysis method and reagent
JP2021096268A (en) Method for measuring soluble interleukin-2 receptor and agent for measurement
JP7225713B2 (en) Method for producing latex particles for anti-streptolysin O measurement
CN104535758A (en) Method for coupling polypeptide or protein to microsphere in covalent mode
JP2020076691A (en) Anti-streptolysin o measurement reagent
WO2020095759A1 (en) Method for producing latex particles for measuring anti-streptolysin o antibody
JP2003344410A (en) Immuno-measurement reagent and immuno-measurement method
JPS60177265A (en) Detection of immunoglobulin of antibody by class
JP3786543B2 (en) Immunological reagent
JP2010014586A (en) Measurement method and measurement reagent kit of hemoglobin inside excrement specimen
JP2004325414A (en) Method and kit for measuring immunity
JPS63122957A (en) Latex coagulating method for detecting anti-streptococcus deoxyribonuclease b
JPH11344494A (en) Immunological agglutination reaction reagent and method for suppressing prozone phenomenon by using the same
JP3328058B2 (en) Method for producing immunodiagnostic drug
JPH0750110B2 (en) Immunoassay
EP0718627B1 (en) A process for preparing diagnostic reagent for syphilis
JPH09304386A (en) Manufacture of immunity diagnostic drug and immunity diagnostic drug obtained
JPH11337550A (en) Immunity measurement reagent and immunity measuring method
JPH10311830A (en) Immunoassay reagent and immunoassay

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211015

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221031

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230123

R151 Written notification of patent or utility model registration

Ref document number: 7225713

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R151